Question 1

Is Tirzepatide legal in Canada?

Accepted Answer

Tirzepatide is offered by Helixx as a research chemical for laboratory and educational use only. It is not approved or sold as a drug, supplement, or food for human consumption in Canada, and purchasers are responsible for complying with all applicable federal, provincial, and institutional regulations governing the acquisition and use of research materials.

Question 2

How does Tirzepatide differ from semaglutide?

Accepted Answer

Semaglutide is a single-pathway GLP-1 receptor agonist, whereas tirzepatide is a dual GIP and GLP-1 receptor agonist. In the SURPASS-2 head-to-head trial, tirzepatide was superior to semaglutide 1 mg for HbA1c reduction and produced greater weight loss.2 You can compare our Ozempic (Semaglutide) listing for the single-agonist reference.

Question 3

What makes it a "dual agonist"?

Accepted Answer

Tirzepatide activates two incretin receptors, GIP and GLP-1, from a single peptide structure. Pharmacology studies show it is an imbalanced, biased agonist that binds GIP with native-like affinity while binding GLP-1 more weakly and signaling with a bias toward cAMP generation.1 Researchers exploring even broader incretin coverage sometimes compare it to the triple agonist Retatrutide.

Question 4

How should Tirzepatide be stored for research?

Accepted Answer

Keep the lyophilized vial refrigerated and protected from light for short-term storage, and frozen for long-term storage. Once reconstituted with sterile or bacteriostatic water for research, keep the solution refrigerated, avoid repeated freeze-thaw cycles, and use it within the stability window established by your own laboratory data.